Filing Overview
Registrant: Blue Water Vaccines Inc. (metadata identifies Onconetix, Inc.; the filing itself names Blue Water Vaccines Inc.). This Form 8-K reports an event dated June 24, 2022 and was filed June 30, 2022. The registrant is an emerging growth company listed on Nasdaq under ticker BWV.
Business Context and Reporting Period
The filing concerns the scheduling of the company’s 2022 annual meeting of stockholders. It does not present quarterly or annual financial results.
Financial Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics.
Material Changes and Corporate Actions
- The Board approved August 22, 2022 as the date of the 2022 annual meeting.
- The filing states that the company would provide the meeting’s exact time, location, and voting matters in a subsequent proxy statement.
- Stockholder proposals under Exchange Act Rule 14a-8 were required to be received by 5:00 p.m. Eastern Time on July 11, 2022, for potential inclusion in the proxy materials.
- Director nomination proposals were required to be received by 5:00 p.m. Eastern Time on July 9, 2022, subject to the company’s bylaws and applicable requirements.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management discussion, risk disclosures, contingencies, or unusual financial items. The principal disclosure is procedural and relates to annual-meeting scheduling and stockholder nomination deadlines.
Investor Verification Items
- Verify the registrant identity: the provided metadata names Onconetix, Inc., while the filing names Blue Water Vaccines Inc. and identifies ticker BWV.
- Review the subsequent proxy statement for the annual meeting’s final time, location, voting matters, and solicitation details.
- Confirm whether any Rule 14a-8 proposals or director nominations were submitted by the stated deadlines.
- Consult the company’s financial filings for revenue, losses, cash position, liquidity, debt, and financing needs, none of which are disclosed in this Form 8-K.